GSA Capital Partners’s Cabaletta Bio CABA Stock Holding History

GSA Capital Partners’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.08M	Buy	668,563 +106,837	+19%	+$351K	0.13%	149
2026 Q1	$1.51M	Buy	561,726 +257,734	+85%	+$716K	0.09%	279
2025 Q4	$666K	Buy	+303,992	New	+$753K	0.06%	627
2024 Q4	–	Sell	-26,976	Closed	-$127K	–	1633
2024 Q3	$127K	Buy	+26,976	New	+$156K	0.01%	1467
2023 Q3	–	Sell	-38,919	Closed	-$502K	–	1514
2023 Q2	$502K	Buy	+38,919	New	+$422K	0.05%	730
2021 Q3	–	Sell	-33,753	Closed	-$290K	–	1449
2021 Q2	$290K	Buy	33,753 +22,253	+194%	+$219K	0.03%	968
2021 Q1	$128K	Buy	+11,500	New	+$140K	0.02%	978

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

GSA Capital Partners's CABA Position: Q2 2026 in Review

GSA Capital Partners increased its Cabaletta Bio (CABA) stake by 19% in Q2 2026, buying an estimated $351K and bringing the position to 668,563 shares worth $2.08M. The position accounts for 0.13% of the portfolio, ranked #149.

GSA Capital Partners first reported a position in CABA in Q1 2021 and has held it in 7 quarters since. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

GSA Capital Partners held 668,563 shares of Cabaletta Bio worth $2.08M as of Q2 2026.
GSA Capital Partners bought 106,837 Cabaletta Bio shares in Q2 2026, an estimated $351K.
Cabaletta Bio made up 0.13% of GSA Capital Partners's portfolio in Q2 2026, its #149 holding.
GSA Capital Partners first reported a position in Cabaletta Bio in Q1 2021 and has held it in 7 quarters since.
140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.